CX3CR1 and metabolic dysfunction-associated steatohepatitis: In line with this, Ly6C+/CX3CR1+/CD88+ moDCs also account for HDC expansion occurring at the onset of experimental NASH, confirming the previous implication of moDC in sustaining liver injury and inflammation in experimental models of chronic steatohepatitis [11].